Is Dyne Therapeutics Inc (NASDAQ: DYN) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Dyne Therapeutics to Present at February Investor Conferences.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

Dyne Therapeutics Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Dyne Therapeutics Inc is $1.49B. A total of 1.08 million shares were traded on the day, compared to an average of 0.61 shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, DYN has seen 6 BUY and 0 SELL insider trades, representing the acquisition of 815,900 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 33 SELLs from insiders. Insiders purchased 1,133,930 shares during that period but sold 470,622.

In the most recent transaction, McNeill Jonathan sold 20,000 shares of DYN for 24.53 per share on Jan 26. After the transaction, the Chief Business Officer now owns 143,618 company shares. In a previous transaction on Jan 26, Scalzo Richard William sold 13,000 shares at 24.34 per share. DYN shares that SVP, Head of Finance & Admin. owns now total 124,228.

Among the insiders who sold shares, Farwell Wildon disposed of 100 shares on Jan 26 at a per-share price of $25.00. This resulted in the Chief Medical Officer holding 168,996 shares of DYN after the transaction. In another insider transaction, Kersten Dirk bought 1,714,285 shares at $17.50 per share on Jan 09. Company shares held by the Director now total 6,416,793.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for DYN in the last 3 months, the mean price target is $34.50 with high estimates of $56.00 and low estimates of $20.00. In terms of 52-week highs and lows, DYN has a high of $25.50 and a low of $6.40.

As of this writing, DYN has an earnings estimate of -$0.9 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.73 per share and a lower estimate of -$1.08. The company reported an EPS of -$1.08 in the last quarter, which was -33.30% lower than expectations of -$0.81.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. DYN’s latest balance sheet shows that the firm has $376.57M in Cash & Short Term Investments as of fiscal 2021. There were $32.64M in debt and $28.72M in liabilities at the time. Its Book Value Per Share was $2.48, while its Total Shareholder’s Equity was $368.20M.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DYN is Buy with a score of 5.00.

Most Popular

Related Posts